BioCryst Pharmaceuticals (BCRX) CEO Charlie Gayer reaffirmed the company's commercial and development trajectory during a Jefferies fireside chat, highlighting continued growth for its oral HAE drug ORLADEYO and progress for late-stage candidate navenibart. For overseas distributors and clinic buyers, the update signals a stable supply-chain outlook for ORLADEYO and a potential new injectable competitor in the HAE prophylaxis market by late 2028.
ORLADEYO Revenue Guidance Maintained
BioCryst kept full-year ORLADEYO revenue guidance at $625 million to $645 million after Q1 revenue of $148.3 million. Gayer said Q1 was in line with expectations, reflecting typical insurance dynamics. The drug generated $602 million in revenue last year, driven by its oral profile and patient-focused commercialization. Gayer noted that a little less than half of ORLADEYO patients switched from injectable prophylaxis, while just over half came from new patient starts or those moving from on-demand treatment to prophylaxis.
Pediatric Launch Delayed by Manufacturing Issue
BioCryst's pediatric ORLADEYO launch was delayed by a batch-specific manufacturing issue. Gayer said the root cause has been identified and the issue was isolated to one batch, with no safety concerns. Manufacturing will resume soon, and the company will update customers when product is in pharmacies. Early pediatric prescriptions have been ahead of expectations, including all four weight-based strengths of the pediatric pellets. Gayer said the pediatric contribution could be on or ahead of plan once product is available.
Navenibart Phase 3 Enrollment on Track
Enrollment in the ALPHA-ORBIT Phase 3 trial for navenibart is expected to finish by end of June, with final patients completing the 12-month blinded period by end of June 2027. Top-line data for both six- and 12-month results are expected in Q3 2026, keeping the company on track to file a BLA by end of 2027, with a likely launch in late 2028. In long-term Phase 2 data, navenibart showed a 92% reduction from baseline in mean attack rate for three-month dosing and 90% for six-month dosing. The commercial presentation is expected to be a two-milliliter autoinjector, with one injection every three months or two injections every six months.
Competitive Landscape and Market Opportunity
Gayer said navenibart is designed as a kallikrein inhibitor with dosing every three or six months, contrasting with current injectable options like Takhzyro (every two weeks) and Andembry (monthly). The company sees the largest opportunity among roughly 5,000 U.S. patients already on injectable prophylaxis. Navenibart has shown essentially no reported injection site pain in Phase 1 and Phase 2 studies, attributed to a formulation without citric acid. Gayer said a "home run" result would include consistent effect across patients, meaningful clinical improvement, and narrowing in on the right dose. BioCryst assumes a strong competitive profile for Pharvaris's oral HAE candidate deucrictibant but still expects ORLADEYO to reach $1 billion in peak U.S. sales.
What Buyers Should Watch
For overseas importers and distributors, the key signals are: ORLADEYO's stable revenue guidance and consistent payer mix (60% commercial, 20% Medicare Part D, 20% other) indicate reliable demand for oral HAE prophylaxis. The pediatric launch delay is temporary but may affect short-term supply. Navenibart's Phase 3 progress and potential late-2028 launch could create a new injectable option with less frequent dosing and reduced injection site pain, appealing to clinics and patients. BioCryst remains open to in-licensing later-stage assets with lower clinical and regulatory risk, but is unlikely to pursue gene therapy, gene editing, or cell therapy.
Source: Read the original report | Published: June 06, 2026